Search Results - pastan

4 Results

Sort By:

Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents

Abstract: Human mesothelin is overexpressed by various cancers such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, and gastric cancers. This selective expression on certain cancers suggests that mesothelin is an excellent target for anticancer therapeutics. However, a large fragment (“the shed portion”) of mesothelin is constantly...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Masanori Onda, Tapan Bera, Mitchell Ho

Keywords(s): ANTIBODY, CANCER, CAR, chimeric antigen receptor, diagnostic, IMMUNOCONJUGATES, IMMUNOTOXINS, MESOTHELIN, Pastan, therapeutic

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent

Abstract: Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Xiu Fen Liu, Tapan Bera, Masanori Onda, Mitchell Ho

Keywords(s): ANTIBODY, Bispecific T-cell engager, BITE, CANCER, CAR, chimeric antigen receptor, diagnostic, Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, therapeutic

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Therapeutic Immunotoxins with Increased Half-Life and Anti-Tumor Activity

Abstract: Recombinant Immunotoxins (RITs) are chimeric molecules composed of an antigen binding domain and toxin. The antigen binding domain component targets the cancer cell and delivers the toxin component to the cell. However, the efficacy of RITs is limited by their short half-life once they are in the patient. To address this problem, investigators...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Zeliang Zheng

Keywords(s): Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, Recombinant Immunotoxins, RITs

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity

Abstract: Recombinant immunotoxins (RITs) constitute a promising solution to hematologic cancers (e.g., Multiple Myeloma [MM]). RITs are chimeric proteins composed of a targeting domain fused to a bacterial toxin. Upon binding to a cancer cell displaying the target antigen, RITs are internalized, metabolized and the released toxin kills the cell. While...

Published: 5/21/2024 | Inventor(s): Ira Pastan

Keywords(s): Abd, Albumin Binding Domain, antibody conjugate, B-cell Maturation Antigen, BCMA, Hematologic Cancer, Mm, MULTIPLE MYELOMA, Pastan, Recombinant Immunotoxin, Rit

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology